(Bold for FDA approved)
• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis
• Blocks dopamine 3 and 4 receptors, which may contribute to sulpiride’s actions
• Possibly blocks presynaptic dopamine 2 autoreceptors more potently at low doses, which could theoretically contribute to improving negative symptoms of schizophrenia as well as depression
• Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior
• Drug-induced parkinsonism, akathisia
• Prolactin elevation, galactorrhea, amenorrhea
• Sedation, dizziness, sleep disturbance, headache, impaired concentration
• Dry mouth, nausea, vomiting, constipation, anorexia
• Impotence
• Tardive dyskinesia
• Risk of potentially irreversible involuntary dyskinetic movements may increase with cumulative dose and treatment duration
• Rare hypomania
• Palpitations, hypertension
• Weight gain
• Rare neuroleptic malignant syndrome may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability with elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure
• Rare seizures
• As a class, antipsychotics are associated with an increased risk of death and cerebrovascular events in elderly patients with dementia; not approved for treatment of dementia-related psychosis
common
common
• Wait
• Wait
• Wait
• For drug-induced parkinsonism, add an anticholinergic agent
• Beta blockers, benzodiazepines, or serotonin 2A antagonists (e.g., mirtazapine, cyproheptadine) may reduce akathisia
• Reduce the dose
• For sedation, give at night
• Switch to an atypical antipsychotic
• Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia
• Metformin may help prevent or reverse antipsychotic-induced weight gain
• Schizophrenia: 400–800 mg/day in 2 doses (oral)
• Predominantly negative symptoms: 50–300 mg/day (oral)
• Intramuscular injection: 600–800 mg/day
• Depression: 150–300 mg/day (oral)
• Different formulations may be available in different markets
• Tablet 200 mg, 400 mg, 500 mg
• Intramuscular injection 50 mg/mL, 100 mg/mL
• Should periodically reevaluate long-term usefulness in individual patients, but treatment may need to continue for many years
• No
• Use with caution; drug may accumulate
• Sulpiride is eliminated by the renal route; in cases of severe renal insufficiency, the dose should be decreased and intermittent treatment or switching to another antipsychotic should be considered
• Use with caution
• Use with caution
• Some patients may tolerate lower doses better
• Although conventional antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with behavioral symptoms of dementia such as agitation
• Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events
• Not recommended for use in children under age 15
• 14 and older: recommended 3–5 mg/kg per day
• There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding
• Potential risks should be weighed against the potential benefits, and sulpiride should be used only if deemed necessary
• Psychotic symptoms may worsen during pregnancy and some form of treatment may be necessary
• Atypical antipsychotics may be preferable to conventional antipsychotics or anticonvulsant mood stabilizers if treatment is required during pregnancy
• Some drug is found in mother’s breast milk
• Recommended either to discontinue drug or bottle feed
• Immediate postpartum period is a high-risk time for relapse of psychosis
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera